Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
| Autor: | Massard, C. *, Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C.J., Petrylak, D.P., Attard, G., Shen, L., Fizazi, K., de Bono, J. |
|---|---|
| Zdroj: | In Annals of Oncology January 2017 28(1):90-95 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|